𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Rituximab therapy and autoimmune disorders: Prospects for anti–B cell therapy

✍ Scribed by Gregg J. Silverman; Stuart Weisman

Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
155 KB
Volume
48
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

New prospects for autoimmune disease the
New prospects for autoimmune disease therapy: B cells on deathwatch
✍ E. William St.Clair; Thomas F. Tedder 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 211 KB

Dr. St.Clair has served on the advisory boards of Genentech, Cellective Therapeutics (now owned by MedImmune), and Human Genome Sciences. Dr. Tedder has Tedder has received consulting fees (more than $10,000 per year) from Cellective Therapeutics (now owned by MedImmune), has given expert testimony

Rituximab therapy for chronic lymphocyti
Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia
✍ Giovanni D'Arena; Luca Laurenti; Silvana Capalbo; Alfonso Maria D'Arco; Rosaria 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

Autoimmune hemolytic anemia (AIHA) is a well-known complication of chronic lymphocytic leukemia (CLL). In recent years the anti-CD20 monoclonal antibody rituximab has been used for the therapy of steroid-refractory AIHA and autoimmune thrombocytopenia, either idiopathic or in association with CLL. W